Markets
markets

Yum! Brands misses Q2 estimates as US demand weakens

Yum! Brands posted a miss across the board, reporting lower-than-expected Q2 results amid a slowdown in consumer spending at its key US franchises.

Revenue rose 9.6% year over year to $1.93 billion, slightly below analyst estimates of $1.94 billion. Adjusted earnings per share came in at $1.44, also missing the $1.46 expected, while same-store sales grew 2% globally, falling short of the 2.3% consensus compiled by FactSet.

The fast-food giant behind KFC, Pizza Hut, and Taco Bell posted mixed results across its brands.

Taco Bell is doing okay. The brand, which is responsible for ~38% of the companys revenue, saw US same-store sales rise 4%, down from 5% growth a year ago. But over at KFC and Pizza Hut, things aren’t so rosy: both saw their US same-store sales slip 5%.

For KFC specifically, competition in the fried chicken arena has never been so intense, with chains like Chick-fil-A, as well as a flood of newcomers like Raising Cane’s, Dave’s Hot Chicken, and Church’s Chicken, clucking at its heels.

As a broader pullback in consumer spending and rising ingredient costs weigh on margins, Yum! and its rivals have leaned into budget meals to lure cost-conscious diners, including Taco Bell’s $5 to $9 meal boxes.

The fast-food giant behind KFC, Pizza Hut, and Taco Bell posted mixed results across its brands.

Taco Bell is doing okay. The brand, which is responsible for ~38% of the companys revenue, saw US same-store sales rise 4%, down from 5% growth a year ago. But over at KFC and Pizza Hut, things aren’t so rosy: both saw their US same-store sales slip 5%.

For KFC specifically, competition in the fried chicken arena has never been so intense, with chains like Chick-fil-A, as well as a flood of newcomers like Raising Cane’s, Dave’s Hot Chicken, and Church’s Chicken, clucking at its heels.

As a broader pullback in consumer spending and rising ingredient costs weigh on margins, Yum! and its rivals have leaned into budget meals to lure cost-conscious diners, including Taco Bell’s $5 to $9 meal boxes.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.